CARLSBAD, Calif.-- Invitrogen, maker of research tools for gene cloning and expression, has been granted exclusive worldwide license to market a line of products incorporating Vyrex's reading frame independent epitope tagging technology. Invitrogen will market products for research and development containing Vyrex's Universal DNA, Universal Epitope, or antibodies that recognize the epitope.
Vyrex claimed that the Universal Epitope tagging system could allow biologists to accelerate functional genomics by eliminating the need for full-sequence characterization and reading frame determination. The technology employs a DNA sequence that encodes the same polypepes and gene products.
Invitrogen also announced that it has appointed Donald Grimm to its board of directors. Grimm has more than 23 years of experience in pharmaceutical management at Eli Lilly and Hybritech.
Grimm is founder of Strategic Design, a consulting group focused on strategic planning, and has recently served as the West Coast representative for Copenhagen Capacity, a Danish trade group focused on biotechnology and medical devices. Previously he was chief executive officer of both Telios Pharmaceuticals and Hybritech.